Friday, December 17, 2010

Is UHPLC Worth All The Hype

Is UHPLC Worth All The Hype
UHPLC or Ultra high performance liquid chromatography can be a technique, or sort of chromatography that’s differentiated from Non HPLC from the method which the separation takes place. The HPLC or UHPLC takes place by using a pump that transfers the substance through the mobile phase as well as the column along with a different sort of detector. Shorter columns are possible for the reason that columns are far more densely packed. Gravity can’t be used again because of the density of the column material.
High performance Liquid Chromatography is used within the laboratory to be able to separate one substance from another and also to analyse what that substance may be. This is achieved for medical, for business, or for law enforcement procedures so just about any type of business today might use UHPLC.
The detection method currently in use signifies that a specific amount of retention time is needed and understanding that the pump instead of gravity can be used to maneuver the analyte. Regular column chromatography often requires a longer column in comparison with the HPLC since particles in HPLC are much smaller and much more densely packed, permitting a better look considering that the separation is far better.
Normal chromatography effects the separation from the analytes determined by their absorption from the analyte by a stationary surface. HPLC or UHPLC offers a much increased pressure, which is necessary in order to get the mobile phase as well as the analyte with the columns. The pumps will be different inside the pressure that they offer but they are measured through the ability they must obtain a consistent flow rate and to provide a consistent pressure for that movement from the substance to get analyzed.

A Digital HPLC Flowmeter Makes System Calibration Easier


Meeting tough FDA standards for HPLC system IQ OQ PQ validation as well as ongoing PV (performance verification) calls for properly installed, calibrated, and maintained equipment. A digital liquid hplc flowmeter such as the FlowCal 5000 is proven to be a convenient and accurate tool to calibrate HPLC pump flow rates, simplifying the calibration and validation procedures. Pump flow rates from 25 mL/min down to as low as 0.05 ml/min can be measured with an accuracy of ± 1 % of the flow rate. This type of tool saves time and labor compared with using a timer while manually collecting the effluent for measurement by weight or volume. In addition, the data collected is independent of operator technique and is therefore both more accurate and more precise.
When checking into digital HPLC flow meters laboratory technicians should determine if the models being considered will deliver accurate data at the flow rates typically used and have a traceable calibration certificate. In addition, the flow meter must be compatible with all brands of HPLC systems used in the lab. All wetted parts should be able to safely handle common HPLC solvents. The flow meter should have an appropriate interface such as an RS232 port for connection to a printer or PC for printing and archiving in accordance with good laboratory practices (GLP).
Installation and Maintenance
Although they are highly accurate, digital flow meter performance is adversely affected by improper mounting and poor maintenance. Citing the FlowCal 5000 as an example, several mounting configurations are available and supported by hardware supplied with the unit. Regardless of the mounting method, the unit must be within 10 degrees of vertical and with suitable space available for placing the collection vessel below the flow meter. Wall mounting, free-standing and stack system options are the most commonly used although in some instances an adapter kit can be employed to mount the unit on wide necked reagent bottles.
While GLP requires annual recalibration, flow meter accuracy can quickly deteriorate with improper use.
For example, dirty sensing tubes can trap bubbles and create false readings. In cases where bubbles are observed during operation the quick remedy is turning the meter off and letting it drain, then return it to operation. This suggests that the number one rule is to keep the sensing tube clean using supplied equipment for this important function. Another good practice is to institute a standard operating procedure specifying that flow meters be cleaned every two weeks when they are in constant use. Flow meters such as the FlowCal 5000 are shipped with a cleaning kit and directions for carrying out this function, a procedure that is usually completed within 15 to 30 minutes. If flow meters are not to be used over a week or more they should be flushed with ethanol to prevent algae growth.
Record Keeping
One method to archive data in order to properly respond to FDA inquiries involves connecting the flow meter to a PC using the RS-232 interface. This allows operators to record flow meter readings electronically, such as in an Excel document using the Windows HyperTerminal program. The process collects data and displays it using HyperTerminl.exe, copies it on a clipboard and pastes it into Excel for analysis. Step-by-step details for this process are available from FlowCal equipment providers such as Tovatech.

How will 2011 spell out for LPO business?


How will 2011 spell out for LPO business?

The LPO Program today releases its forecast of the 2011 Legal Process Outsourcing market showing high growth in all areas of the legal community. The main users of LPO continue to be Corporate Law Departments, who are forecast to add $129m of spending in 2011. Law firms are shaking off traditional caution and are fuelling 41% of the projected growth. On these forecasts, it is expected that at least 9 high profile deals will be announced by law firms in the next 12 months.
Public Sector use of LPO is the largest new source of growth in 2011. Political considerations and ongoing caution across all sectors will support the growth of the on-shore delivery market, though India remains the most common delivery location.
Commenting on the forecast, Edward Brooks, of The LPO Program, said "The maturing of the supplier community is perfectly timed for buyers of LPO services. While very attractive cost savings open the door for LPO, the long term strategic advantages explain why a very sophisticated sector is actually signing on the line."
The LPO Program says that the Global LPO market is expected to grow 34% ($217m) in 2011, from a base of $640m, to $857m. Corporate legal departments are the largest drivers of the growth; closely followed by UK-based law firms. US law firms are very active in the market but continue to be cautious relative to their UK counterparts.
Overall the US market continues to be constrained by political considerations. Ongoing discussions in Congress continue to create an environment in which potential buyers of Legal Process Outsourcing services are treading cautiously. This will remain an issue until at least 2012 and is holding back US organizations from getting the full value of outsourcing.
The UK public sector will be the major new growth opportunity for the LPO market as it reacts to extreme cost pressures. While this segment of the market has been a regular user of external legal resources, full scale outsourcing of in-house legal functions is now firmly on the agenda across the UK, in particular within Local Authorities.
Reputation risk and political considerations will benefit low cost, onshore locations, namely Northern Ireland for the UK and relatively low cost US states e.g. Utah, Oklahoma. India continues to be the preferred offshore delivery location, with countries such as the Philippines and South Africa hampered by relatively low volumes of skilled resources.
Edward Brooks continued, "Ongoing economic uncertainty makes any organization wary of adding fixed costs and fixed capacity, and that makes LPO even more attractive. All deals benefit from significant cost savings, but market leaders are taking a strategic decision based on the value of having a variable cost base and a flexible talent pool."
The long term strength of the LPO market also looks very robust. Edward Brooks added, "We have seen a significant increase in the percentage of "Active Observers" in the market. We classify "Active Observers" as being subscribers to The LPO Program who move from being recipients of our free services and newsletters to paying for basic access the Program's Research Services. Active Observers are typically from organizations that are carrying out early stage analysis of their LPO options. Given the complexity of LPO projects, the deals that the Active Observers are contemplating are not likely to hit the market until 2012, but it is a healthy indicator of the future size of the market."
Survey Methodology Summary. The 2011 Projections are based on Total Contract Values of LPO deals that are currently being investigated by LPO Program clients. The LPO Program's client base closely reflects the shape of the legal services market in English speaking countries, so the core data can then be extrapolated across the full market to provide an estimate of the global market. We classify LPO as being where an organization changes how its legal activities are delivered, either to an in-house, captive model or a third party delivery location.

What is Clinical Research Outsourcing?


What is Clinical Research Outsourcing?
Clinical Research Outsourcing can be described as the moving away from traditional, expensive and time-consuming in-house Research and Development to creating strategic partnership with external vendors who partner to deliver credible data at within timelines, complying with international regulatory standards and most importantly within the R&D budgets of the product. These clinical partners are popularly known as Contract Research Organizations (CROs).

The rise in Clinical Research Outsourcing It has been observed globally that there is a steady rise in the trend to outsource Clinical Research activities by Drug Development companies. A number of factors have contributed to this growing trend to partner with CROs.

The current scenario sees drug
developers face capacity constraints due to the increase in volumes in global clinical trials. Worldwide development may have taken a boost but many major pharmaceutical and biotechnology companies have not consciously increased their in-house personnel for internal clinical research.
A dramatic increase in the birth of small and medium sized Pharma and biotech companies who conduct atleast one clinical trial per 6 to 12 months have given way to outsourcing a much larger part of their total research budgets to experts who bring in the required overall clinical research expertise that falls outside their area of capabilities.

Many Sponsor companies are now of the opinion that CROs can definitely provide an advantage with respect to cost, timelines and varied therapeutic expertise. Kunal Bhatt, Global-BDM resonates the current trend that there is a rise in outsourcing
clinical trials to local CROs who have the local regulatory and operations expertise to conduct clinical trials and reduce the turnaround time for the completion of the study which is one of the main concerns of any Sponsor outsourcing the trial.

India Inc. and Outsourcing India since a while now has been considered as the Mecca of clinical outsourcing in South East Asia. ClinACE lists down the probable reasons for this: Huge population A good treatment nave population size with an advantage of varied therapeutic conditions. Affordable R&D costs and state-of-the-art amenities in large private and certain government hospitals attract global
pharmaceutical and biotech companies to conduct trials in India ensuring faster recruitment rates which ascertains reduced timelines. Data acceptability by foreign regulators which used to be of grave concern now seems to be a thing of the past. Indian CROs have repeatedly generated good quality, internationally accepted data by participating in various global multicentre studies. Companies are more confident about the safety of their molecule and primary data while outsourcing clinical trials to India. An overall Cost effectiveness and strict and complete adherence to timelines set has given way to a positive new outlook when contemplating on outsourcing to India.
In the current drug development environment, it is of prime essence that sponsors want to reduce the time taken to get a molecule from its nascent stage to commercialization the shift from the traditional in-house Research and Development to strategic, competency-based partnerships promises to help sponsors meet these challenges.

INDUSTRIAL PROCESS EVALUATION AND SELECTION FOR TABLETS:


INDUSTRIAL PROCESS EVALUATION AND SELECTION FOR TABLETS:
Determine the unit operations needed to manufacture the tablets.
1. Mixing or Blending:
Materials that have similar physical properties will be easier to form a uniform mix or blend and will not segregate as readily as materials with large differences.
Parameters to consider:
·         Mixing or blending technique: Diffusion (tumble), convection (planetary or high intensity), or pneumatic (fluid bed) techniques can be used to mix or blend materials. Determine the technique that is required for the formulation or process objective. It may be different, depending on whether you are mixing the drug and excipient for a direct compression formulation or adding the lubricant (e.g., magnesium stearate) to the granulation.
·         Mixing or blending speed: Determine the intensity (low/high shear) and/or speed (low/high/optimal shear) (rpm) of the mixing or blending. Mixing the drug and excipient will require more intense mixing than adding the lubricant to the final blend.
·         Mixing or blending time: How much mixing or blending is required to obtain a uniform mixture? The mixing or blending time will be dependent on the mixing or blending technique and speed. Experiments should be done to determine if the materials can be over mixed, resulting in demixing or segregation of the materials. Demixing can occur due to the physical property differences (e.g., particle size distribution and density). For example, demixing can occur in a direct compression formulation in which the drug substance is micronized (5 microns) and the excipient are granular (500–1000 microns).
·         Drug uniformity: Content uniformity is usually performed to determine the uniformity of drug throughout the mix or blend. Representative samples should be taken throughout the mix or blend. The sampling technique and handling of the materials are key in obtaining valid content uniformity results. Segregation of the sample can occur by over handling, resulting in inaccurate results. For the final blend (blend prior to compression), the sample taken should be equivalent to the weight of a single tablet.
·         Excipient uniformity: Besides drug uniformity, excipient needs to be uniform in the granulation or blend. Two key excipient are:
R      Lubricant: The lubricant needs to be distributed uniformly in the mixture/granulation for the high-speed compression operation. Uneven distribution of the lubricant can result in picking and sticky problems during compression. It can also lead to tablet performance problems (low dissolution due to excessive lubricant in some tablets).
R      Color: The colorant(s) need(s) to be evenly distributed in the mixture so that the tablets have a uniform appearance (e.g., color, hue, and intensity). The coloring agent may need to be prescreened or more uniformly dispersed in the blend prior to compression to avoid speckling or shading of the color.
·         Equipment capacity/load: The bulk density of materials or granules will affect the capacity of the equipment. If an excipient in the formulation affects the density of the final blend to a greater extent than any other ingredient, then a well-controlled density specification for that excipient may be warranted. Test different-sized loads in the mixer/blender (e.g., 30, 50, and 70% of working volume) for optimal mixing or blending. Undercharging or overcharging a blender can result in poor drug or tablet lubricant distribution.
2. Wet Granulation
What type of wet granulation technique will be used? Will it be low shear (e.g., Hobart), high shear (e.g., Diosna, GEI-Collette) or fluid bed (e.g., Glatt, Fluid Air)? Each technique will produce granules with different physical properties and will require monitoring of different processing parameters. Wet granulation parameters to be considered during development and validation are:
·         Binder addition: Should the binder be added as a granulating solution or dry like the other excipient? Adding the binder dry avoids the need to determine the optimal binder concentration and a separate manufacture for the binder solution.
·         Binder concentration: The optimal binder concentration will need to be determined for the formulation. If the binder is to be sprayed, the binder solution needs to be dilute enough so that it can be pumped through the spray nozzle. It should  also be sufficiently concentrated to form granules without over wetting the materials.
·         Amount of binder solution/granulating solvent: How much binder or solvent solution is required to granulate the material? Too much binder or solvent solution will over wet the materials and prolong the drying time. The amount of binder solution is related to the binder concentration.
·         Binder solution/granulating solvent addition rate: Define the rate or rate range at which the binder solution or granulating solvent can be added to the materials. Can the granulating solution be dumped into the mixer or does it have to be metered in at a specific rate?
·         Mixing time: How long should the material be mixed to ensure proper formation of granules? Should mixing stop after the addition of the binder or solvent solution or should additional mixing be required? Granulations that are not mixed long enough can form incomplete or weak granules. These granules may have poor flow and compression properties. On the other hand, over mixing the granulation can lead to harder granules and a lower dissolution rate.
·         Granulation end point: How is the granulation end point determined? Is it determined or controlled by granulation end point equipment (e.g., ammeter or wattmeter)? Is it controlled by specifying critical processing parameters? For example, a drug or excipient mixture may be granulated by adding a predetermined amount of water (granulating solution) at a certain rate. The granulation is completed after mixing for a set time after the water has been added.
3. Wet Milling
Does the wet granulation need to be milled to break up the lumps and enhance drying of the granulation? Wet granules that have a wide aggregate range can lead to inefficient drying (long drying times and partially dried large granules or lumps). Factors to consider are:
·         Equipment size and capacity: The mill should be large enough to delump the entire batch within a reasonable time period to minimize manufacturing time and prevent the material from drying during this operation.
·         Screen size: The screen needs to be small enough to delump the material, but not too small to cause excessive heating of the mill, resulting in drying of the granulation.
·         Mill speed: The speed should be sufficient to efficiently delump the material without straining the equipment.
·         Feed rate: The feed rate of the wet granulation is interrelated to screen size and mill size and speed.
4. Drying
The type of drying technique (e.g., tray, fluid bed, and microwave) required for the formulation needs to be determined and justified. The type of technique may be dependent on such factors as drug or formulation properties and equipment availability. Changing dryer techniques could affect such tablet properties as hardness, disintegration, dissolution, and stability. The optimal moisture content of the dried granulation needs to be determined. High moisture content can result in
(1) Tablet picking or sticking to tablet punch surfaces and 
(2) Poor chemical stability as a result of hydrolysis.
An over dried granulation could result in poor hardness and friability. Moisture content analysis can he performed using the conventional loss-on-drying techniques or such state-of-the-art techniques as near infrared (NIR) spectroscopy.
·         Inlet/outlet temperature: The inlet temperature is the temperature of the incoming air to the dryer, while the outlet temperature is the temperature leaving the unit. The inlet temperature is critical to the drying efficiency of the granulation and should be set high enough to maximize drying without affecting the chemical/physical stability of the granulation. The outlet temperature is an indicator of the granulation temperature and will increase toward the inlet temperature as the moisture content of the granulation decreases (evaporization rate).
·         Airflow: There should be sufficient airflow to ensure removal of moisture laden air from the wet granulation. Insufficient airflow could prolong drying and affect the chemical stability of the drug. Airflow and the inlet/outlet temperature are interrelated parameters and should be considered together.
·         Moisture uniformity: The moisture content could vary within the granulation. Heat uniformity of the dryer (e.g., tray), amount of granulation per tray, and incomplete fluidization of the bed are factors that could affect the moisture uniformity of the granulation.
·         Equipment capability/capacity: The load that can be efficiently dried within the unit needs to be known. A larger load will require more moisture to be removed
·         on drying and will affect the drying time. In the case of fluid bed drying, a maximum dryer load is that load above which the dryer will not fluidize the material.
5. Milling
The milling operation will reduce the particle size of the dried granulation. The resultant particle size distribution will affect such material properties as flow, compressibility, disintegration, and dissolution. An optimal particle size/size distribution for the formulation will need to be determined. Factors to consider in milling are:
·         Mill type: What mill type (e.g., impact or screen) should be used? Each has several variants, depending on the means to reduce the particles. The type of mill can generate a different particle size/size distribution. Particle size testing will need to be conducted and the results examined when substituting mill types.
·         Screen size: The selected screen size will affect the particle size. A smaller screen size will produce a smaller particle size and a greater number of fines.
·         Mill speed: What is the optimal mill speed? A higher mill speed will result in a smaller particle size and possibly a wider particle size distribution. It can also generate more heat to the product, depending on the screen size and feed rate, which could affect the stability of the product.
·         Feed rate: The feed rate is dependent on the mill capacity, screen size, and mill speed.
6. Lubrication
Selection of lubricant:  what kind of lubricant should be used? Grade of the lubricant used. Compatibility with other ingredients. Amount of lubricant added:  How much lubricant is required? Too much lubricant will form hydrophobic layer on the tablet resulting in dissolution problems. Mixing time:  How long should the material is mixed to ensure proper formation? Should mixing stop after the addition of the lubricant or should additional mixing be required? If not mixed long enough form problems like chipping, capping, etc.
7. Tablet Compression
Compression is a critical step in the production of a tablet dosage form. The materials being compressed will need to have adequate flow and compression properties. The material should readily flow from the hopper onto the feed frame and into the dies. Inadequate flow can result in “rat holing” in the hopper and/or segregation of the blend in the hopper/feed frame. This can cause tablet weight and content uniformity problems. As for the compressibility properties of the formulation, it should be examined on an instrumented tablet press. Factors to consider during compression are as follows:
·         Tooling: The shape, size, and concavity of the tooling should be examined based on the formulation properties and commercial specifications. For intagliated (embossed) tablets, factors such as the position of the intagliation on the tablet and the intagliation depth and style should be examined to ensure that picking of the intagliation during compression or fill-in of the intagliation during coating does not occur.
·         Compression speed: The formulation should be compressed at a wide range of compression speeds to determine the operating range of the compressor. The adequacy of the material’s flow into the dies will be determined by examining the tablet weights. Is a force feeder required to ensure that sufficient material is fed into the dies?
·         Compression/ejection force: The compression profile for the tablet formulation will need to be determined to establish the optimal compression force to obtain the desired tablet hardness. The particle size/size distribution or level of lubricant may need to be adjusted in order to have a robust process on a high-speed compressor.
      The following in-process tests should be examined during the compression stage:
      1.  Appearance
      2.  Hardness
      3.  Tablet weight
      4.  Friability
      5.  Disintegration
      6.  Weight uniformity

8. Tablet Coating
Tablet coating can occur by different techniques (e.g., sugar, film, or compression). Film coating has been the most common technique over recent years and will be the focus of these section Key areas to consider for tablet coating include the following:
·         Tablet properties: Tablet properties such as hardness, shape, and intagliation (if required) are important to obtain a good film-coated tablet. The tablet needs to be hard enough to withstand the coating process. If tablet attrition occurs, the tablets will have a rough surface appearance. For tablet shape, a round tablet will be easier to coat than tablets will multiple sides or edges because of the uniformity of the surface. For intagliated tablets, the intagliation style and depth should be developed to prevent fill-in or chipping of the intagliation.
·         Equipment type: The type of coater will need to be selected. Conventional or perforated pan and fluid bed coaters are potential options.
·         Coater load: What is the acceptable tablet load range of the equipment? Having too large a pan load could cause attrition of the tablets because of the overall tablet weight in the coater. In the case of a fluid bed coater, there may not be sufficient airflow to fluidize the tablets.
·         Pan speed: What is the optimal pan speed? This will be interrelated to other coating parameters, such as inlet temperature, spray rate, and flow rate.
·         Spray guns: The number and types of guns should be determined in order to efficiently coat the tablets. The spray nozzles should be sized properly to ensure even distribution over the tablet bed and to prevent clogging of the nozzles. The location and angle of the spray gun(s) should be positioned to get adequate coverage. Having the guns positioned too close together can lead to a portion of the tablets to be over wet.
·         Application/spray rate: The optimal application/spray rate should be determined. Spraying too fast will cause the tablets to become over wet, resulting in clumping of tablets and possible dissolution of the tablet surface. Spraying too slowly will cause the coating materials to dry prior to adhesion to the tablets. This will result in a rough tablet surface and poor coating efficiency.
·         Tablet flow: The flow or movement of the tablets in the coater should be examined to ensure proper flow. There should be sufficient tablet bed movement to ensure even distribution of the coating solution onto the tablets. The addition of baffles may be required to provide adequate movement of tablets for tablet coating.
·         Inlet/outlet temperature and airflow: These parameters are interrelated and should be set to ensure that the atomized coating solution reaches the tablet surface and then is quickly dried.
·         Coating solution: The concentration and viscosity of the coating solution will need to be determined. The solution will need to be sufficiently diluted in order to
·         Spray the material on the tablets. The concentration of the coating solution will also determine the amount and volume of solution to be applied to the tablets. The stability of the coating solution should be investigated to establish its shelf life.
·         Coating weight: A minimum and maximum coating weight should be established for the tablet. Sufficient coating material should be applied to the tablets to provide a uniform appearance; however, it should not be great enough to cause fill-in of the intagliation. 
·         Residual solvent level: If solvents are used for tablet coating, the residual solvent level will need to be determined. Appearance testing of the tablets is critical during the coating operation. Items to look for include the following:
1.  Cracking or peeling of the coating 
2.  Intagliation fill-in
3.  Surface roughness
4.  Color uniformity
5. Coating efficiency should be determined for the coating operation. The efficiency will determine the amount of coating solution overage that may be required.
9. In-process tests
1.  Moisture content of “dried granulation”
2.  Granulation particle size distribution
3.  Blend uniformity
4.  Individual tablet/capsule weight
5.  Tablet hardness
6.  Tablet thickness
7.  Disintegration
8.  Impurity profile
10. Finished product tests
1.  Appearance
2.  Assay
3.  Content uniformity
4.  Tablet hardness
5.  Tablet friability
6.  Impurity profile
7.  Dissolution
These key test parameters are the yardsticks by which the major processing variables in solid dosage forms are evaluated. Some processing variables are:
·         Mixing time and speed in blenders and granulators
·         Solvent addition rates in granulators
·          Time, temperature, and airflow conditions in dryers and coaters
·          Screen size, feed rate, and milling speed in mills
·         Machine speed and compression force in tablet presses
Process validation testing is generally done on the first three batches of product made in production-size equipment. Revalidation testing is only done when a “significant” change has occurred. A significant change is one that will alter the in-process or final product specification established during the validation program or a change in formula, process, or equipment.
Related Posts Plugin for WordPress, Blogger...